Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug EPI-326 enters human testing for tough cancers

NCT ID NCT07462377

Recruiting now Disease control Sponsor: EpiBiologics Source: ClinicalTrials.gov ↗

First seen Mar 19, 2026 · Last updated May 13, 2026 · Updated 12 times

Summary

This early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood and look for early signs of tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Astera Cancer Care

    RECRUITING

    East Brunswick, New Jersey, 08816, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Los Angeles

    RECRUITING

    Los Angeles, California, 90025, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START New York Long Island

    NOT_YET_RECRUITING

    Lake Success, New York, 11042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon and HCA Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • South Texas Accelerated Research Therapeutics (START)

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EGFR EGFR EPIDERMAL GROWTH FACTOR EPIDERMAL GROWTH FACTOR RECEPTOR EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION HEAD AND NECK HEAD AND NECK CANCER HEAD AND NECK CANCERS HEAD AND NECK CANCERS HEAD AND NECK SQUAMOUS CELL CANCER HEAD AND NECK SQUAMOUS CELL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC HNSCC NON SMALL CELL NON-SMALL CELL LUNG CANCER NON-SMALL-CELL LUNG NSCLC (NON-SMALL CELL LUNG CANCER)